The Johnson & Johnson vaccine was the third to receive the approval for emergency use in the USA, after Pfizer/BioNTech and Moderna.
The US Food and Drug Administration (FDA) has issued emergency use authorization for the vaccine developed by Johnson&Johnson against the new variant of Coronavirus (Covid-19).
FDA announced its decision on the vaccine on Friday, which was recommended for approval by an independent panel of infectious diseases experts.
It is announced that the Covid-19 vaccine, developed by Johnson&Johnson pharmaceutical company and administered as single shot, was approved for emergency use.
Johnson&Johnson’s vaccine is the third authorized for emergency use in the USA, following those developed by Pfizer/BioNTech and Moderna.
It was announced that Johnson&Johnson's single-shot Covid-19 vaccine, which was tested on 44,000 people, was 66 percent effective, providing strong protection against disease and death.
According to current data from the Center for Disease Control and Prevention (CDC), which tracks Covid-19 vaccination statistics in the USA, the total number of vaccines administered nationwide has exceeded 70 million.
According to the latest data by CDC, more than 47 million people in the country received the first dose and more than 22 million received the second dose of Covid-19 vaccine.